profit from every $100 of sales.
$0$100
Vor Biopharma
$19.98+0.50% today
+6.8% in 1 year
1-year low $6.861-year high $25.10
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Vor Biopharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$696 million of profit last year.
SalesProfit
Vor Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vor Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Vor Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -93 | -126 | -121 | -372 | |
| -91 | -123 | -118 | -369 | |
| -92 | -118 | -117 | -696 | |
| -46.60 | -35.00 | -34.03 | -70.50 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 299 | 198 | 143 | 464 |
| Cash | 58 | 31 | 82 | 396 |
| Total debt | 39 | 36 | 32 | 3 |
| Total liabilities | 49 | 47 | 46 | 628 |
| 251 | 151 | 97 | -164 | |
| 2 | 3 | 3 | 10 | |
| -25.5% | -53.4% | -74.5% | – | |
| -36.7% | -78.2% | -120.9% | 423.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -85 | -100 | -100 | -143 | |
| 8 | 1 | 0 | 1 | |
| -94 | -101 | -100 | -144 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 13 | 10 | 19 |
Valuation
- –
- –
- –
- -1.0×
- –
- –
- 0.2×
- -11.7%
- -56.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -84.6%
- 43.2%
- 72.7%
- -150.0%
- -84.7%
- –
Growth
- –
- –
- −43.8%
- –
- +51.8%
Financial health
- 0.4×
- -0.02
- 0.6%
- –
- 18.20
- 18.20
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Bottom 21%of 871
Bottom 10%of 985
What analysts expect
- Average price target
- $38.50
- Range
- $31.00 – $46.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.73 | -0.75 | +2.7% |
| Mar 30, 2026 | 44.50 | -1.14 | +4,003.5% |
| Nov 13, 2025 | -3.33 | -3.06 | −8.8% |
| Aug 12, 2025 | -43.60 | -11.40 | −282.5% |
| May 14, 2025 | -0.26 | -0.25 | −4.0% |
| Mar 20, 2025 | -0.44 | -0.34 | −29.4% |
| Nov 7, 2024 | -0.40 | -0.40 | +0.0% |
| Aug 8, 2024 | -0.41 | -0.41 | +0.0% |
News
The big winners of the tech wreck are biopharma stocksMarketWatch · Oct 30, 2026Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregationSeeking Alpha · Sep 25, 2026Chinese biopharma stocks jump as U.S. weighs keeping door open to drug dealsCNBC · Sep 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
45No pass
Philip Fisher
38No pass
Peter Lynch
–Not enough data
Joel Greenblatt
42No pass
Charlie Munger
40No pass
Terry Smith
35No pass
Questions about Vor Biopharma
Is Vor Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vor Biopharma AI analysis
What does Vor Biopharma do?
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It is in Biotechnology.
Does Vor Biopharma pay a dividend?
No. Vor Biopharma does not pay a dividend at the moment.
Is Vor Biopharma stock halal?
Questionable. Vor Biopharma sits in a grey zone: its cash and confirmed interest-bearing investments are 32% of its market value, between 30% and 33%. How we check
How has Vor Biopharma stock done over the past year?
Up 6.8% over the past twelve months, to $19.98. It traded between $6.86 and $25.10 and is 20.4% below its high.
Who are Vor Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Vor Biopharma's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.